Fennec Pharmaceuticals Inc. (FENC)

NASDAQ: FENC · Real-Time Price · USD
6.11
-0.03 (-0.49%)
Dec 12, 2024, 4:00 PM EST - Market closed
-0.49%
Market Cap 167.58M
Revenue (ttm) 49.35M
Net Income (ttm) -1.13M
Shares Out 27.43M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 48,814
Open 6.11
Previous Close 6.14
Day's Range 5.92 - 6.19
52-Week Range 3.96 - 11.92
Beta 0.35
Analysts Strong Buy
Price Target 14.00 (+129.13%)
Earnings Date Nov 7, 2024

About FENC

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is ba... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 5, 2001
Employees 29
Stock Exchange NASDAQ
Ticker Symbol FENC
Full Company Profile

Financial Performance

In 2023, Fennec Pharmaceuticals's revenue was $21.25 million, an increase of 1284.50% compared to the previous year's $1.54 million. Losses were -$16.05 million, -32.34% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 129.13% from the latest price.

Price Target
$14.0
(129.13% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...

18 hours ago - GlobeNewsWire

Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Off...

4 weeks ago - Seeking Alpha

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to ...

5 weeks ago - GlobeNewsWire

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...

6 weeks ago - GlobeNewsWire

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...

3 months ago - GlobeNewsWire

Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Robert Andrade - CFO Jeffrey Hackman - CEO and Board Member Conference Call ...

4 months ago - Seeking Alpha

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $...

4 months ago - GlobeNewsWire

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference

4 months ago - GlobeNewsWire

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment t...

4 months ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Management Change

RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian H...

5 months ago - GlobeNewsWire

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy cir...

6 months ago - GlobeNewsWire

Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Rosty Raykov - Chief Executive Officer and Director Robert Andrade - Chief Fina...

7 months ago - Seeking Alpha

Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~

7 months ago - GlobeNewsWire

Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...

7 months ago - GlobeNewsWire

Fennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~

9 months ago - GlobeNewsWire

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com...

9 months ago - GlobeNewsWire

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-in...

9 months ago - GlobeNewsWire

Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price

Fennec released sales guidance for Q4 2023, exceeded analyst expectations. A pending EU launch of PEDMARK® provides a near term opportunity for the Company to finalize an EU partnership. Revenue growt...

10 months ago - Seeking Alpha

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE ...

10 months ago - GlobeNewsWire

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S....

11 months ago - GlobeNewsWire

Fennec Announces Incremental $5 Million Investment from Petrichor

~ Supports Strategic Discussions and Global Launch Activities ~ ~ Extends Access to Additional Undrawn Capital As Needed During Global PEDMARK® Rollout ~ ~ Facilitates Market Expansion into the Adoles...

1 year ago - GlobeNewsWire

Fennec Pharmaceuticals Expands Possible TAM Significantly

Fennec Pharmaceuticals is a commercial-stage biotech company with a single drug, PEDMARK®, which is FDA-approved to reduce the risk of hearing loss in pediatric cancer patients. The company faced chal...

1 year ago - Seeking Alpha

Fennec Pharmaceuticals Inc. (FENC) Q3 2023 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rosty Raykov - Chief Executive Off...

1 year ago - Seeking Alpha